A Phase 2 interventional study of FYU-981 and Topiroxostat in Hyperuricemia, sponsored by Fuji Yakuhin Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-08-21.
Sponsored by Fuji Yakuhin Co., Ltd. · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing dotinurad in Hyperuricemia — 3 open to participants now, 3 under way, 2 of them phase 3. dotinurad · Hyperuricemia.
Among the 11 studies testing dotinurad in Hyperuricemia, this one is the 10th largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 2, and was the 3rd registered.
240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.
Browse Hyperuricemia studies →3 of the 11 studies testing dotinurad in Hyperuricemia are open now, in 4 countries. Recruiting first, the newest first:
Crystalys Therapeutics · Sites in United States
Ages 18–75
Crystalys Therapeutics · Sites in United States, Poland, Spain
Ages 18–75
Saga University · Sites in Japan
Ages 20+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 20 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 5 · Phase 4 1
First in 2014; this study’s year is marked. 2 started in 2016.
This study's enrollment of 24 is below the median of 68 across 193 interventional studies indexed under Hyperuricemia.
Median enrollment 201 across the 11 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 5 most frequent:
Fuji Yakuhin Co., Ltd. is the lead sponsor of 12 studies on the registry; none are open to participants now.
Fuji Yakuhin Co., Ltd. has 5 studies filed under Hyperuricemia — fewer than ten, so there is no comparison to draw.
2 of the studies testing dotinurad in Hyperuricemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07089875Phase 3Crystalys TherapeuticsA Study of Dotinurad Versus Allopurinol in Participants With Gout | 2027-11-29 |
| NCT06834230Saga UniversityEffect of Dotinurad in Hyperuricemia With Hypertension | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing dotinurad in Hyperuricemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the pharmacodynamics, pharmacokinetics and safety of 7-day-repeated doses of FYU-981 administered orally to male hyperuricemic patients with uric acid-overproduction or uric acid-underexcretion type.
In addition, to investigate the additive effects of the combination of FYU-981 and topiroxostat administered orally to male hyperuricemic patients with uric acid-overproduction type.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
FYU-981
Drug: FYU-981
FYU-981
Drug: FYU-981
FYU-981 , Topiroxostat
Drug: FYU-981 · Drug: Topiroxostat
FYU-981
Drug: FYU-981
Also known as: FYX-051
Pharmacodynamics (Amount of uric acid excreted in urine)
Time frame: 1-, 2-, 3-, 4-, 5-, 6-,7-,8- and 9-day
Pharmacodynamics (Renal clearance of uric acid)
Time frame: 1-, 4- and 7-day
Pharmacodynamics (Fractional uric acid excretion)
Time frame: 4- and 7-day
Pharmacodynamics (Maximum delta effective uric acid concentration)
Time frame: 1-, 2-, 3-, 4-, 5-, 6- and 7-day
Pharmacodynamics (Delta area under the serum uric acid concentration-time curve)
Time frame: 1-, 4- and 7-day
Pharmacokinetics (Cmax: Maximum plasma concentration)
Time frame: 1-, and 7-day
Pharmacokinetics (Cmin: Minimum plasma concentration)
Time frame: 1-, 2-, 3-, 4-, 5-, 6- and 7-day
Pharmacokinetics (Tmax: Time to reach the peak plasma concentration)
Time frame: 1-, and 7-day
Pharmacokinetics (T1/2: Elimination half-life of plasma concentration)
Time frame: 1-, and 7-day
Pharmacokinetics (AUC: Area under the plasma concentration-time curve)
Time frame: 1-, and 7-day
Pharmacokinetics (kel: Elimination rate constant)
Time frame: 1-, and 7-day
Pharmacokinetics (Vd/F: Distribution volume / Fraction of dose absorbed)
Time frame: 1-, and 7-day
Pharmacokinetics (CLtot/F: Total clearance / Fraction of dose absorbed)
Time frame: 1-, and 7-day
Pharmacokinetics (MRT: Mean residence time)
Time frame: 1-, and 7-day
Plan to share: No
The record gives a start of Jul 2016, a primary completion of Aug 2017 and a completion of Mar 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dotinurad
Fuji Yakuhin Co., Ltd.